← All trials
NCT04365179
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2020
- Primary completion
- May 30, 2022
- Completion date
- May 30, 2022
- First posted
- Apr 28, 2020
- Last posted
- Apr 28, 2020
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Immune System Key LtdLead sponsor
- University of MiamiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.